LUPIN LIMITED |
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
| 1.595 INR | +0,94 % |
|
+0,08 % | +20,55 % |
Resumen de negocios
- diseño y producción de formulaciones genéricas y de marca;
- producción de ingredientes farmacéuticos activos.
A finales de marzo de 2022, el grupo contaba con 15 centros de producción en India (12), Estados Unidos, México y Brasil.
Las ventas netas se desglosan geográficamente como sigue: India (39,4%), Estados Unidos (34,1%) y otros (26,5%).
Número de empleados: 20 933
Ventas por actividad
| INR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 164 055 | 100,0 % | 166 417 | 100,0 % | +1,44 % |
Ventas por región
| INR en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
India
40,0
%
| 64 596 | 39,4 % | 66 507 | 40,0 % | +2,96 % |
United States
31,0
%
| 56 352 | 34,3 % | 51 584 | 31,0 % | -8,46 % |
Others
29,0
%
| 43 107 | 26,3 % | 48 326 | 29,0 % | +12,11 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/97 | |
Johnny Mikell
PSD | President | - | - |
| Director of Finance/CFO | 59 | 13/08/07 | |
Shahin Fesharaki
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | - | |
| Director/Board Member | 50 | 01/01/96 | |
Ravik Agarwal
IRC | Investor Relations Contact | - | - |
Jon Stelzmiller
PRN | Corporate Officer/Principal | - | - |
Rajeev Sibal
PRN | Corporate Officer/Principal | - | - |
Yashwant Mahadik
HRO | Human Resources Officer | - | 10/07/18 |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
| Director/Board Member | 74 | 27/10/15 | |
Mark McDade
BRD | Director/Board Member | 69 | 28/01/21 |
| Director/Board Member | 50 | 01/01/96 | |
| Chairman | 80 | 01/03/83 | |
| Director of Finance/CFO | 59 | 13/08/07 | |
| Chief Executive Officer | 56 | 01/01/97 | |
| Director/Board Member | 58 | 12/08/20 | |
| Director/Board Member | 62 | 01/08/20 |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 1 | 455 750 104 | 240 790 322 ( 52,83 %) | 0 | 52,83 % |
Información de la empresa
Lupin Ltd.
Kalpataru Inspire Off Western Expressway Highway
400055, Mumbai
+91 22 6640 2323
http://www.lupin.com
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
Nanomi BV
 Nanomi BV Chemicals: SpecialtyProcess Industries Part of Lupin Ltd., Nanomi BV is a Dutch company that manufactures drugs. The private company is based in Oldenzaal, the Netherlands. Okke Franssen has been the CEO of the company since 2016. Nanomi was acquired by Lupin Ltd. on February 03, 2014. |
Chemicals: Specialty
|
Lupin Atlantis Holdings SA
 Lupin Atlantis Holdings SA Pharmaceuticals: MajorHealth Technology Part of Lupin Ltd., Lupin Atlantis Holdings SA is a holding Swiss company that manufactures and distributes pharmaceutical products. The private company is based in Zug, Switzerland. |
Pharmaceuticals: Major
|
Ventas por región
Calificación trading
Calificación Inversor
ESG Refinitiv
A
Venta
Compra
Recomendación promedio
CONSERVAR
Numero de análisis
34
Último precio de cierre
1.580
INR
Precio objetivo promedio
1.516
INR
Diferencia / Objetivo Promedio
-4,06 %
Revisiones del BPA
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| +20,55 % | 8642,51 M | |
| +25,61 % | 660 mil M | |
| +22,82 % | 562 mil M | |
| -5,24 % | 358 mil M | |
| +16,49 % | 322 mil M | |
| +8,28 % | 297 mil M | |
| +13,21 % | 219 mil M | |
| -9,65 % | 196 mil M | |
| +6,40 % | 199 mil M | |
| -8,75 % | 149 mil M |
- Bolsa de valores
- Acciones
- Acción LUPIN
- Empresa Lupin Limited
